Kingsview Wealth Management LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

Kingsview Wealth Management LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 60.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 16,513 shares of the biopharmaceutical company’s stock after selling 24,866 shares during the period. Kingsview Wealth Management LLC’s holdings in Gilead Sciences were worth $1,833,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in Gilead Sciences in the fourth quarter worth approximately $215,000. Sivia Capital Partners LLC lifted its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares during the period. Crestwood Advisors Group LLC boosted its position in Gilead Sciences by 6.4% during the 2nd quarter. Crestwood Advisors Group LLC now owns 15,912 shares of the biopharmaceutical company’s stock valued at $1,764,000 after acquiring an additional 955 shares in the last quarter. Finally, Atlantic Union Bankshares Corp increased its holdings in shares of Gilead Sciences by 4.7% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 183,782 shares of the biopharmaceutical company’s stock valued at $20,376,000 after acquiring an additional 8,300 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 309,280 shares of company stock worth $43,935,470 over the last ninety days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Stock Down 2.1%

GILD stock opened at $145.14 on Friday. The company has a market capitalization of $180.18 billion, a P/E ratio of 21.44, a price-to-earnings-growth ratio of 1.94 and a beta of 0.37. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The firm’s fifty day simple moving average is $137.91 and its 200-day simple moving average is $125.56. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the firm posted $1.90 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Analyst Ratings Changes

A number of brokerages recently weighed in on GILD. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Citigroup increased their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Daiwa Securities Group raised their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Wells Fargo & Company increased their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $156.72.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.